Amylyx Pharmaceuticals Inc (AMLX)
2.055
+0.06
(+2.75%)
USD |
NASDAQ |
May 03, 11:09
Amylyx Pharmaceuticals Cash and Short Term Investments (Quarterly): 371.36M for Dec. 31, 2023
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 371.36M |
| September 30, 2023 | 355.04M |
| June 30, 2023 | 357.28M |
| March 31, 2023 | 345.67M |
| December 31, 2022 | 346.94M |
| September 30, 2022 | 162.59M |
| Date | Value |
|---|---|
| June 30, 2022 | 206.68M |
| March 31, 2022 | 255.20M |
| December 31, 2021 | 96.12M |
| September 30, 2021 | 125.70M |
| December 31, 2020 | 12.88M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
12.88M
Minimum
Dec 2020
371.36M
Maximum
Dec 2023
239.59M
Average
255.20M
Median
Mar 2022
Cash and Short Term Investments (Quarterly) Benchmarks
| Cassava Sciences Inc | 121.14M |
| iRhythm Technologies Inc | 133.76M |
| Bristol-Myers Squibb Co | 9.67B |
| Moderna Inc | 8.604B |
| ACADIA Pharmaceuticals Inc | 438.86M |